China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service agreement with domestic firm Impact Therapeutics, securing exclusive market promotion rights for Impact’s senaparib in mainland China. Under the agreement, Huadong will pay an initial fee of RMB 100 million (USD 14 million) and is committed to potential milestone payments of up to RMB 190 million (USD 27 million) related to regulatory and commercial achievements. Impact will compensate Huadong for market promotion services rendered.
Senaparib, a PARP1 inhibitor developed by Impact, received orphan drug designation (ODD) in the US in August 2022 for its potential use in treating small-cell lung cancer in combination with temozolomide. The drug is currently under regulatory review in China for its application as a maintenance treatment for patients with stage III-IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete or partial remission following first-line platinum chemotherapy.- Flcube.com
